title: Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.
abstract: OBJECTIVE
  To analyze results of 127 patients undergoing myeloablative therapy followed by marrow transplantation for relapsed or refractory Hodgkin's disease.
  
  
  METHODS
  Twenty-three patients had primary refractory disease, 34 were in early first relapse or second complete remission (CR), and 70 had refractory first relapse or disease beyond second CR. Preparative regimens included total-body irradiation (TBI) and chemotherapy (n = 61) or chemotherapy only (n = 66). Sixty-eight patients received autologous marrow, six syngeneic marrow, and 53 allogeneic marrow.
  
  
  RESULTS
  The 5-year actuarial probabilities of survival, event-free survival (EFS), relapse, and nonrelapse mortality for the entire group were 21%, 18%, 65%, and 49%, respectively. HLA-identical allogeneic marrow recipients had a statistically lower relapse rate compared with recipients of autologous marrow, but survival, EFS, and nonrelapse mortality rates were not significantly different. In the multivariate analysis, higher performance status and absence of bulky disease predicted for improved EFS and lower relapse rates, while fewer prior treatment regimens predicted for improved EFS and lower nonrelapse mortality rates. Additionally, the univariate analysis showed that patients who underwent transplantation with disease refractory to chemotherapy or beyond second CR had a worse outcome compared with those who had less advanced disease.
  
  
  CONCLUSIONS
  Outcome with transplantation for patients with Hodgkin's disease is improved if transplantation is performed early after relapse when disease burden is less, tumor chemosensitivity is greater, and the patient is likely to have a better performance status. The use of HLA-matched sibling marrow results in a lower relapse rate and, thus, for some individuals, may be preferable to the use of autologous marrow.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA.
authors.forename: J E
authors.initials: JE
authors.lastname: Anderson
authors.forename: M R
authors.initials: MR
authors.lastname: Litzow
authors.forename: F R
authors.initials: FR
authors.lastname: Appelbaum
authors.forename: G
authors.initials: G
authors.lastname: Schoch
authors.forename: L D
authors.initials: LD
authors.lastname: Fisher
authors.forename: C D
authors.initials: CD
authors.lastname: Buckner
authors.forename: F B
authors.initials: FB
authors.lastname: Petersen
authors.forename: S W
authors.initials: SW
authors.lastname: Crawford
authors.forename: O W
authors.initials: OW
authors.lastname: Press
authors.forename: J E
authors.initials: JE
authors.lastname: Sanders
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D012008:Recurrence; D016019:Survival Analysis; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic; D016896:Treatment Outcome